Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 30 Jan 2025 – 20 Aug 2026, limited by DSP BSE SENSEX Next 30 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | DSP BSE SENSEX Next 30 ETF | Nifty 50 |
|---|---|---|
| 30 Jan 2025 | ₹100.00 | ₹100.00 |
| 18 Mar 2025 | ₹99.84 | ₹98.21 |
| 05 May 2025 | ₹105.83 | ₹105.21 |
| 21 Jun 2025 | ₹110.42 | ₹108.01 |
| 07 Aug 2025 | ₹109.82 | ₹105.79 |
| 23 Sep 2025 | ₹113.64 | ₹108.26 |
| 10 Nov 2025 | ₹115.02 | ₹110.00 |
| 27 Dec 2025 | ₹116.64 | ₹112.01 |
| 12 Feb 2026 | ₹119.79 | ₹111.00 |
| 31 Mar 2026 | ₹107.44 | ₹96.05 |
| 18 May 2026 | ₹120.89 | ₹101.72 |
| 04 Jul 2026 | ₹122.04 | ₹104.39 |
| 20 Aug 2026 | ₹125.26 | ₹104.23 |
| Metric | DSP NAV ₹43.50 Very High risk ★★★★☆ 1Y | Category median Other ETFs · 248 funds |
|---|---|---|
| +11.08% | +3.65% | |
| — | +10.51% | |
| — | +9.28% | |
| — | +11.93% | |
| +15.61% | +10.38% | |
| +13.80% | — | |
| — | +14.30% | |
| — | +13.74% | |
| — | +12.83% | |
| Risk | ||
| 15.34% | 15.45% | |
| 0.30 | 0.28 | |
| 0.42 | 0.41 | |
| -11.44% | -20.59% | |
| Nifty 50 | — | |
| — | +0.80% | |
| — | 1.00 | |
| — | 102.1% | |
| — | 96.4% | |
| 0.23% | 0.32% | |
| ₹45.07Cr | ₹137.31Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| 30 Jan 2025 | — | |
| 30 | — | |
| 44.5% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.